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Abstract 
Transvenous temporary cardiac pacing is a rather old 
but still contemporary life-saving technique, with a unique 
value in the treatment of critically ill patients suffering 
from rhythm disturbances and associated hemodynamic 
compromise. Physicians involved in the management of 
such patients should always keep in mind the indications 
and contraindications of transvenous temporary cardiac 
pacing, and should be at least familiar with the insertion 
technique and the post-insertion care.  
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List of Abbreviations 
 
AMI = acute myocardial infarction; AV = atrio-ventricular; BBB 
= bundle branch block; CHB = complete heart block; ECG = 
electrocardiogram; LAFB = left anterior fascicular block; LBBB 
= left bundle branch block; LPFB = left posterior fascicular 
block; RA = right atrium; RBBB = right branch bundle block; 
RV = right ventricle; SVT = supraventricular tachycardia; SuVT 
= sustained ventricular tachycardia; TCP = temporary cardiac 
pacing; TdP = torsade de pointes 
 
Introduction 
 
Temporary cardiac pacing is a life-saving procedure 
used as a means of electrical stimulation of the heart 
through the use of pacing leads, in order to treat 
dysrhythmias, until they are resolved or until a long-term 
therapy is adopted.1-5 Temporary pacing is effected via 
transvenous, transcutaneous, or epicardial approaches. 
Transcutaneous pacing is delivered via cutaneous adhesive 
pads placed in an anteroposterior position, has the 
advantage of being immediately available for emergency 
cases of asystole but it requires high energy to capture the 
heart, causing significant discomfort to the wake patient, 
and is reserved for those who are comatose or as a bridge 
until transvenous endocardial pacing is rendered 
feasible.1,5,6 Epicardial wires are routinely placed during 
cardiac surgery to provide backup pacing in the event of 
perioperative bradyarrhythmias, but also to diagnose and 
overdrive certain tachyarrhythmias (e.g. atrial flutter).7 
However, the most common and reliable approach to 
temporary pacing is provided with transvenous insertion of 
temporary pacing wire.1-5  
Transvenous temporary cardiac pacing (TCP) was first 
described by Furman et al in 1958 in dogs and in 1959 in 
human beings,8,9 initially for the correction of complete 
heart block, but the indications have subsequently 
expanded to comprise a variety of bradyarrhythmias but 
also a list of tachyarrhythmias, including the diagnosis and 
overdrive suppression of supraventricular and ventricular 
tachycardias.1,3,4 In its most common use of supporting the 
patient with bradycardia, temporary pacing typically 
serves as a bridge to a more definitive solution to a low 
heart rate, such as permanent pacemaker implantation, or 
resolution of a transient or reversible cause, e.g. 
bradycardic effect of drugs, electrolyte disturbance, 
inferior-wall myocardial infarction, etc.  
 
Indications  
 Transvenous temporary cardiac pacing is most 
commonly used to treat symptomatic bradycardia due to 
sinus node dysfunction or atrioventricular (AV) block. In 
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general, indications could be divided into those associated 
with acute myocardial infarction (AMI), and those not 
linked to AMI.1,10 The former are clearly outlined in the 
American Heart Association guidelines for AMI 
management,11 and presented in Table 1. It should be 
noted, that in a patient with AMI, a more aggressive 
management of bradycardia is warranted in order to 
maintain an adequate coronary blood flow in the infarcted 
myocardium. However, special precautions should be 
taken in a patient who has undergone thrombolysis, such 
as using different access site or using transcutaneous 
pacing. Also, in the more recent AHA 2010 Guidelines,12 
for the management of cardiac arrest, the routine use of 
pacing in asystole is listed as a grade III recommendation.  
 
Table 1: Recommendations for Temporary Transvenous 
Pacing in the Course of AMI11 
Class I 
1. Asystole  
2. Symptomatic bradycardia (includes SB with hypotension & 
type I 2o AV block with hypotension not responsive to atropine)
3. Bilateral BBB (alternating BBB or RBBB with alternating 
LAFB/LPFB) (any age) 
4. New or indeterminate age bifascicular block (RBBB with 
LAFB or LPFB, or LBBB) with 1o AV block 
5. Mobitz type II 2o AV block 
Class lla  
1. RBBB and LAFB or LPFB (new or indeterminate) 
2. RBBB with 1o AV block 
3. LBBB, new or indeterminate 
4. Incessant VT, for atrial or ventricular overdrive pacing 
5. Recurrent sinus pauses (>3 s) not responsive to atropine 
Class IIb 
1. Bifascicular block of indeterminate age 
2. New or age-indeterminate isolated RBBB 
Class III 
1. 1o heart block 
2. Type I  2o AV block with normal hemodynamics 
3. Accelerated idioventricular rhythm 
4. BBB or fascicular block known to exist before acute MI 
 
AMI = acute myocardial infarction; AV = atrio-ventricular; BBB 
= bundle branch block; LAFB = left anterior fascicular block; 
LBBB = left bundle branch block; LPFB = left posterior 
fascicular block; RBBB = right branch bundle block 
 
In the setting of an AMI, the benefits of transvenous 
TCP should be weighed and balanced against the higher 
risk for bleeding if the patient has recently received 
thrombolysis or is on heparin and/or other antithrombotics 
during the process of primary percutaneous coronary 
intervention (PCI). If the patient remains hemodynamic-
cally stable, transcutaneous pads could be used as backup 
instead. In general, due to the adoption of rapid reperfusion 
therapies over the recent years (e.g. primary PCI),11 and 
also due to observed higher risk of complications of TCP 
in the setting of AMI (e.g. ventricular tachyarrhythmias),13 
and with the availability of transcutaneous pacing, 
transvenous TCP use has significantly declined to <1%.14  
 
Table 2. Indications for Temporary Cardiac Pacing 
 
AV = atrioventricular; CHB = complete heart block; PPM = 
permanent pacemaker; SuVT = sustained ventricular 
tachycardia; SVT = supraventricular tachycardia  
 
 Beyond the use of pacing in the setting of AMI, the 
indications of transvenous TCP are similar to those of 
permanent pacing,15 especially when the latter is not 
immediately available or finally not indicated, such as in 
bradycardia due to reversible causes. Nevertheless, in such 
cases transvenous TCP should be reserved for patients with 
hemodynamic compromise, episodes of asystole or 
tachyarrhythmias in response to bradycardia, such as 
polymorphic ventricular tachycardia in the form of 
torsarde de pointes (TdP) in the setting of long QT interval. 
The application of TCP in asymptomatic and 
hemodynamically stable patients with good escape 
rhythms may render these individuals pacemaker 
dependent, and in case pacing fails, asystole could occur. 
In addition, there is the risk of infection in the access site, 
that could possibly be used later for permanent pacing.1,3 
A special cautionary note concerns patients, more 
commonly women, presenting with complete heart block, 
who have increased propensity to develop TdP 
unassociated with QT prolonging drugs.16 Thus, in patients 
presenting with acquired complete heart block and low 
heart rate, even when hemodynamically stable or 
oligosymptomatic, it may be prudent to use prophylactic 
transvenous TCP in all of them, while waiting for a 
permanent pacemaker, to avoid this worrisome scenario of 
bradycardia-induced long QT and TdP.  
 
Reversible causes of bradycardia, where transvenous TCP 
should be considered, are listed in Table 3.3,4,15 
 
Table 3. Temporary Pacing for Reversible Causes of 
Bradycardia 
 
1.  Metabolic or electrolytes abnormalities (hypothyroi-
dism, hypothermia, hyperkalemia)  
2.  Drug induced bradycardia (beta blockers, calcium 
channel blockers, digitalis, amiodarone) 
Acute MI Bradyarrhythmias Tachyarrhythmias 
Asystole Asystole / CHB Torsades de pointes 
CHB Symptomatic sinus 
bradycardia (< 40 bpm) 
SVT 
Mobitz II 
AV block 
Prolonged sinus pauses 
(>3-4 s) 
SuVT 
(see Table 1) PPM failure/ 
replacement 
 
 (see Table 3)  
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3.  Injury to the sino-atrial node or other parts of the 
conduction system, after cardiac surgery, heart 
transplantation, radiofrequency ablation of arrhythmias or 
cardiac trauma during motor vehicle accident; ischemia 
(inferior-wall AMI) 
4.  Other diseases associated with temporal injury to the 
conduction system, such as Lyme’s disease, or 
endocarditis with an aortic valve abscess (early ECG sign: 
1o AV block).  
 
 Transvenous TCP might be necessary in patients fitted 
with a permanent pacemaker if permanent pacing fails, or 
when pacemaker-dependent patients undergo pulse 
generator replacement.1 Moreover, TCP might be 
considered in ambiguous cases to verify the potential 
benefit of possible permanent pacing. In rare cases dual-
chamber DDD TCP with use of an additional atrial lead 
with a preformed j-curve positioned in the right atrial 
appendage under fluoroscopy guidance has been employed 
to improve cardiac output in patients who have lost AV 
synchrony;1,3,4  alternatively, VDD pacing via a single 
atrial-sensing ventricular-pacing lead has been proposed 
for use in patients with acute sepsis and heart failure;18 at 
the same time there are scarce reports about the use of 
temporary biventricular pacing in cases of refractory 
cardiogenic shock.19 Elective use of transvenous TCP has 
been reported in patients with underlying conduction 
abnormality (such as trifascicular block), who undergo 
non-cardiac surgery or high risk angioplasty in the right 
coronary artery.1  When TCP is unexpectedly needed 
during the performance of a PCI procedure, pacing can be 
accomplished faster using the coronary artery guidewire, 
as an alternative to insertion of a transvenous temporary 
pacemaker.20 Finally, during newer types of percutaneous 
procedures, such as transcatheter aortic valve implantation 
(TAVI), transvenous TCP is employed for both 
prophylaxis for the occurrence of heart block (standby 
pacing) and for facilitation of balloon valvuloplasty and/or 
balloon-expansion of the artificial valve (rapid pacing).21,22  
 An important, albeit less known or less frequently 
employed, use of transvenous TCP relates to the 
management of tachyarrhythmias. In the setting of sick 
sinus syndrome or prolonged QT interval, rapid pacing 
(90-110 bpm) could minimize the incidence of atrial 
fibrillation, and polymorphic ventricular tachycardia 
(TdP) respectively. In addition, several tachyarrhythmias, 
such as supraventricular tachycardia, atrial flutter or 
monomorphic ventricular tachycardia could be terminated 
with overdrive pacing, which involves pacing at slightly 
faster rates than the tachycardia rate.1,2,23 Overdrive pacing 
requires expertise, as inadvertent implementation could 
lead to acceleration of the tachycardia.1,2  
 
Contraindications  
 Transvenous TCP should be avoided when the possible 
risks outweigh the potential benefits, such as in 
asymptomatic stable patients or in those which excessive 
bleeding risk, especially after thrombolysis administration. 
The presence of a prosthetic tricuspid valve is an absolute 
contraindication, while infarction of the right ventricle 
could minimize the possibility of successful pacing 
capture.1 
 
Insertion Technique  
The physicians who are credentialed to place a 
temporary pacemaker should be familiar with the insertion 
equipment (puncture needle and sheath), electrode-
catheters and connectors, and the external pulse generator 
available in their own hospital settings. Apart from 
understanding the indications of temporary cardiac pacing 
(Tables 1-2) and acquiring the technical skill of safe vessel 
puncture and lead insertion, another very important aspect 
is how capable and knowledgeable the physician is in order 
to recognize the morphology of the endocardial 
electrograms of the superior vena cava, right atrium, and 
right ventricle and use this electrocardiographic (ECG) 
monitoring to guide proper pacing lead positioning.2, 24  
Transvenous Access. Access sites for transvenous 
pacing include the internal jugular, subclavian, femoral 
and even the antecubital or brachial veins. The internal 
jugular vein is favored by some as it may be associated 
with fewer complications and spares subclavian access for 
future permanent pacemaker placement.1,25 However, 
patient convenience and maintenance of site sterility may 
be less desirable. The subclavian route appears to be a 
more stable position and provides a more convenient site 
for patient mobility.26 The femoral vein is generally 
undesirable due to increased incidence of deep vein 
thrombosis and infection. However, during cardiac 
procedures performed in the catheterization or the 
electrophysiology laboratory, this site is a readily 
accessible site, albeit for cases requiring pacing coverage 
for a very short duration. If the need for temporary pacing 
coverage is expected to be of longer duration, then the 
temporary pacing lead initially inserted via the femoral 
access should be exchanged with a more stable position, 
e.g. the subclavian route, at the end of the main procedure. 
Finally, the external jugular, branchial or antecubital and 
femoral veins may be used in special circumstances, 
mostly after thrombolysis.1 With the availability of 4 o 5Fr 
balloon-tipped electrode catheters, the use of the 
antecubital (median basilic) vein may be a safer and more 
convenient approach, through which a transvenous TCP 
lead can be inserted and placed endocardially with relative 
ease when guided by ECG monitoring (see below) 
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conferring fewer complications, especially in patients at 
risk for hemorrhage or when a less well trained physician 
is involved.  
Guidance. After obtaining transvenous access, a single 
balloon-tipped bipolar electrode-catheter (4-5Fr) may be 
used.2, 27 This temporary pacing lead can be introduced 
transvenously without fluoroscopy in a bedside procedure, 
similar to a Swan-Ganz catheter insertion aided by blood 
flow directing placement of the balloon-tipped catheter or 
via electrocardiographic monitoring. Of course, placement 
of a temporary pacing wire with use of fluoroscopy is 
easier and safer due to direct visualization of the lead, and 
it would be preferable if a procedure room is readily 
available next to the cardiac care unit or in the vicinity of 
the patient’s whereabouts, or it may become necessary 
when the other approaches fail and the patient is then 
transferred to the catheterization or electrophysiology 
laboratory to perform the procedure. In this case a hard-
tipped bipolar electrode catheter can be used and 
maneuvered under visualization into the right ventricular 
apex.  
Without fluoroscopic imaging, a balloon-tipped pacing 
lead is employed and advanced “blindly” with the external 
pulse generator switched on, guided by the length of the 
catheter insertion and/or observing after each pacing spike 
for the appearance of ventricular capture with a left bundle 
branch morphology on 12-lead ECG confirming the 
correct placement of the lead within the right ventricle. 
While any site within the right ventricle, except for the 
high right ventricular outflow sites, will provide adequate 
pacing threshold and safe temporary pacing, placement of 
the pacing wire at the right ventricular apex will afford the 
greatest lead stability.  
Newer active fixation temporary pacing wires have 
been advocated for better lead stabilization, but require 
more operator expertise and their safety has not been 
corroborated. Others have proposed the use of a permanent 
pacing lead inserted with use of a stylet similar to the 
procedure of a permanent pacing lead insertion and 
connected to a used or old permanent pacemaker pulse 
generator adhered externally to the chest. This approach 
may be particularly useful for pacemaker-dependent 
patients undergoing pacing lead extraction and pacemaker 
removal due to infection and thus bridged until a new 
permanent pacemaker is implanted on the contralateral 
side. 28-31  
Electrocardiographic Monitoring. A more effective 
and safe, albeit a bit more time consuming, approach 
utilizes the pacing bipolar electrode catheter as an ECG 
lead to monitor the advancement and correct endocardial 
placement of the pacing lead by observing the changes in 
the endocardial electrogram pattern during passage of the 
catheter through the right heart chambers.2, 24 This can be 
easily accomplished by connecting the distal (negative) 
pole of the lead with one of the precordial leads (e.g. V1 or 
V2) of the ECG with use of alligator connectors (crocodile 
clips) to record a unipolar ECG lead; alternatively, the 
distal electrode can be connected to the right arm lead and 
the proximal electrode to the left arm lead to record a 
bipolar lead I electrocardiogram. Recording of a QS 
pattern indicates traversing the tricuspid valve, at which 
point the balloon is deflated and the lead is advanced with 
a clock-wise rotation to direct it towards the apex and make 
contact with the endocardium, which is confirmed by the 
appearance of ST elevation (injury pattern) on the 
endocardial electrogram (Fig. 1). If the balloon is not 
deflated in time, the lead will further advance to the 
outflow tract and the pulmonary artery; a position in the 
outflow tract is prone to dislodgement and less reliable 
pacing. Upon recording of a QS/ST elevation type of 
intracardiac electrogram, connection of the lead is 
switched to the external pacemaker device and pacing 
threshold testing is performed. A pacing threshold < 1 mA 
attests to excellent endocardial contact of the pacing lead.  
 
 
Figure 1. Lead V2 displays the endocardial electrogram (EGM) 
during passage of the pacing lead from the right atrium (left 
panel) to the right ventricle (right panel); transition is indicated 
by the QS pattern of the EGM and the ST elevation (arrow).  
 
 This ECG guided approach can only be applied in 
patients who have an underlying native (escape or other) 
rhythm and, of course, not in patients with ventricular 
asystole. During the insertion process, a loop in the right 
atrium may be formed and pose difficulty in further 
advancing the lead; this is best avoided by paying attention 
to the length of the lead being advanced (>30-40 cm), in 
which case the lead is withdrawn (with the balloon 
deflated) and the process repeated. During monitoring of 
the endocardial ECG, the appearance of an R wave should 
raise the suspicion of possible perforation, when the lead 
is immediately withdrawn and the patient monitored for 
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possible hemopericardium or tamponade; in the majority 
of cases this remains uneventful. After final lead 
placement, some have suggested partial inflation of the 
balloon that could reduce the risk of perforation. At this 
point obtaining a 12-lead ECG can further confirm correct 
lead placement close to the right ventricular apex, by 
recording a pacing rhythm with LBBB pattern with 
superior (left) axis; recording a RBBB pattern indicates 
epicardial pacing either via a perforating lead or a lead 
inserted inadvertently into the middle cardiac or other 
coronary vein (Fig. 2). Note also that echocardiography 
may be another, less often used option, for lead guidance.4 
 With the lead is in place, the external generator is 
securely connected to it, and the appropriate pacing mode 
is selected (usually VVI). The capture and sensing 
thresholds are being tested as described above. In an 
emergency, the highest output should be tried first (e.g. 15-
20 mA); it should then be gradually reduced until capture 
is lost. If the situation is not an emergency, the rate is set 
10-20 beats/min above the intrinsic heart rate, and the 
output is initially set very low and then gradually increased 
until capture occurs or set high and gradually decreased 
until capture is lost. The output should be set to a value at 
least 2-5 times higher than the threshold to ensure a safe 
margin for any change that occurs in the capture threshold, 
which is usually less than 1 mA. A position with low 
pacing threshold (<1 mA) should be sought; a high pacing 
threshold >5 mA in the right ventricular lead indicates a 
need for repositioning. A slightly higher capture threshold 
is acceptable for atrial leads because they are less stable 
than ventricular leads.  
 
 
Figure 2. When the pacing lead lies within the right ventricle, 
pacing produces a LBBB-like QRS morphology (left panel); 
when it has inadvertently entered the left ventricle or an 
epicardial coronary vein (e.g. the middle cardiac vein), pacing 
produces a RBBB-like QRS morphology (right panel). LBBB = 
left bundle branch block; RBBB = right bundle branch block.  
 
 To check the sensing threshold (if it is needed in the 
demand pacing mode), the pacing rate should be set lower 
than the intrinsic heart rate. The value of the sensitivity 
setting should then be gradually increased until the 
pacemaker fails to sense the intrinsic activity and 
consequently begins firing. The sensing threshold is 
usually more than 5 mV in the ventricle and is much lower 
in the atrium. The final sensitivity should then be set at a 
low value (high sensitivity) to effect adequate sensing of 
native electrical activity including extrasystoles and thus 
avoid inappropriate pacing and arrhythmia triggering. On 
the other hand, the sensitivity setting should not be too low 
(indicating high sensitivity) as the external pacemaker 
devices are more prone to electromagnetic interference 
from various external sources and equipment in the 
intensive care unit (e.g. respirators, monitors, even mobile 
or wireless phones, etc.) and thus risk pacemaker 
inhibition. In case of pacemaker dysfunction in the form of 
absent pacing, one should discern between visible 
pacemaker spikes that do not capture, which points to 
increased threshold or lead dislodgment, and absent pacing 
spikes which indicates disconnected leads or pacemaker 
inhibition due to oversensing; when proper connections are 
confirmed, increasing the sensitivity setting or selecting a 
VOO mode might correct the oversensing problem. 
Finally, the AV interval in AV sequential pacing is usually 
set between 100 and 200 ms, which is comparable to a 
normal PR interval.4 
 
Entry Site / Peri-procedural Care 
 At the end of the procedure, the introducing sheath 
should be carefully removed from the vein and moved all 
the way back to the proximal end of the pacing lead, since 
leaving the introducer in place may be an important gate of 
bacteria entry and infection. A first suture is placed at the 
entry site to secure the lead in place, but also a second 
suture is even more important to be placed at a small wire 
loop created just a bit more proximally (to prevent lead 
dislodgment from accidental pulling), all contained within 
the sterile field which should subsequently be covered with 
a sterile dressing. The remaining length of the pacing wire 
can be looped and secured in the ipsilateral arm of the 
patient together with the connectors and the external 
pacing device, so that the patient could ambulate early, if 
clinically deemed appropriate, rather than sentenced to 
being bed ridden. Leaving the sheath in place and using 
long sleeves over the pacing wire has been suggested by 
some as convenient for repositioning the pacing wire in 
case of displacement, in analogy to the sleeve used for the 
Swan-Ganz catheter. This strategy should though be 
limited to those patients who are bed ridden, 
hemodynamically unstable, perhaps on respiratory support 
in the intensive care unit, but this approach may confer an 
increased risk of infection. For patients who are otherwise 
stable, except for their need for temporary pacing, an 
entirely different strategy is proposed, as described above, 
rendering them capable for early ambulation.  
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Complications 
Although the complication rate of temporary cardiac 
pacing has been reported to be as high as 32-35% in British 
and Danish studies,32, 33  especially for less experienced 
operators, more commonly this rate is limited to 2%-10%. 
Complications may comprise local access bleeding, air 
embolism, nerve damage, pneumothorax or hemothorax 
during the subclavian puncture, hemopericardium and 
pericardial tamponade, atrial and ventricular arrhythmias 
during catheter insertion, including atrial fibrillation and 
occasionally ventricular tachycardia and ventricular 
fibrillation; this is why an external defibrillator should 
always be present during TCP.1,3,4 A more common 
complication relates to post-procedural lead displacement 
resulting in loss of pacing capture and need for re-
intervention. An important and avoidable, albeit risky, 
complication relates to infection leading to bacteremia and 
endocarditis. Thus, an aseptic technique and antiseptic 
measures during the procedure, avoidance of the femoral 
route and diligent local care and vigilance post-
procedurally are of utmost importance to avoid this 
potentially dangerous complication. Emergence of 
pericardial pain and an audible pericardial rub dictates a 
need for repositioning; fortunately, rarely does this 
condition lead to tamponade.  
 
Post-Procedural Patient Care  
Most studies have shown a relatively low rate of 
infection during the first week of transvenous temporary 
pacing. However, when there is need for longer duration 
of temporary pacing, the complication rate may increase. 
Infection can be reduced by avoiding femoral access and 
maintaining high standards of local access care. There has 
accumulated significant experience from the time when 
electropharmacological tesing was routinely performed in 
patients with ventricular tachyarrhythmias to test the 
efficacy of anti-arrhythmic drugs, before the implantable 
defibrillator became more widely available. At that time, 
after the first (primary) electrophysiology study, a small (4 
or 5F) bipolar temporary wire was routinely inserted via 
the subclavian vein and placed at the right ventricular apex, 
which stayed in place for the duration of the period of drug 
testing via repeat sessions of programmed stimulation, 
which occasionally could last 3-4 weeks. Carefully sterile 
initial procedure and meticulous local care of the access 
site (cleaning and dress change), together with daily 
cardiac auscultation for the appearance of pericardial rub 
and periodic threshold testing of the pacing wire and/or 
recording of the endocardial electrogram when needed, 
resulted in only rare occurrence of infections or other 
complications, or at least these measures permitted early 
recognition of such complications. Finally, recording the 
time of replacement of batteries of the external pacemaker 
device by placing a label on the device and watching for 
battery depletion, as well as securing and conducting 
surveillance of the lead connections to the pacemaker 
device are also other important measures to both prevent 
and detect further problems.   
The connections of the lead with the pulse generator 
should be securely attached and the generator should be 
secured in place to prevent an unexpected drop in the 
ground. Attaching it to the patient’s arm would be ideal, in 
an ambulatory patient.4,34 Thorough care should be 
implemented to prevent infection. Use of antiseptic and a 
sterile, preferably transparent, dressing at the access site is 
of utmost importance; the entry site should be cleaned and 
the dressing changed daily.34 Routine use of prophylactic 
antibiotics is not necessary unless there is a sign of 
infection, pacing is prolonged (>7 days) or femoral access 
is used. Twelve-lead-ECG, pacing and sensing thresholds 
should be assessed daily, as they fluctuate over time. 
Threshold testing in pacemaker dependent patients (with 
>90% pacing) should be performed with caution. 
Whenever there is a suspicion of lead dislodgement a new 
chest x-ray should be ordered.1,4,34 Indeed, transvenous 
TCP, using standard temporary wires, has been plagued 
with loss of capture more frequently compared to the very 
low risk with permanent pacemakers. The patient should 
be maintained on telemetry for the duration of temporary 
pacing. This caveat together with the declining skill and 
capability of operators, mainly due to lack of training,35, 36 
all culminating into an inordinate rate of complications of 
transvenous TCP in some, mostly European, countries, is 
the main reason why some clinicians have declared this 
life-saving procedure as an “orphan” and advocated a 24-
hour permanent pacemaker implantation service.36,37 
However, this strategy may lead to a hastened decision 
regarding the need for permanent pacemaker, poses the 
risk of missing indolent infection with subsequent severe 
consequences of device infection, and also missing other 
serious underlying disorders which may come up when the 
routine pre-procedural test results become available at a 
later time. Since, there is definitely a way to make TCP a 
safe procedure and durable process, educational bodies and 
societies should aim at restructuring the training guidelines 
for TCP, rather than compromising patient safety with 
hasty and frivolous approaches.  
 
Physician Training 
Currently, there are limited guidelines on training 
requirements to achieve competency on temporary cardiac 
pacing. The Accreditation Council for Graduate Medical 
Education (ACGME) guidelines recommend that residents 
perform 6 cardiac pacing attempts during residency 
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training, either in patients or simulators, but make no 
distinction between transcutaneous or transvenous 
pacing.38 According with the joint statement released in 
1994 by the American College of Physicians, American 
College of Cardiology (ACC), and American Heart 
Association (AHA) regarding clinical competence in 
insertion of a transvenous TCP, a minimum of 10 TCP 
procedures are required of the trainee.39 Over the recent 
years, it has become apparent that simulation techniques 
are adequate and effective in measuring procedural 
competency and may thus constitute a substitute of “hands 
on” patient practice and experience as a training tool for 
physicians in various procedures, including training on 
transvenous TCP.38 In the US, medical and surgical 
residents usually receive training right from the start in 
their first year of residency how to place a transvenous 
TCP lead, and thus there is usually no need to call upon a 
cardiology fellow or attending to perform the procedure 
except for difficult cases. However, in Europe and other 
parts of the world, this task is relayed to a cardiologist 
rather than a physician of other specialties. In either case, 
adequate training is the key to successful and safe 
performance of this life-saving procedure.40 In addition to 
cardiologists, other specialists with an aptitude for this 
procedure may be emergency medicine physicians, 
intensivists, and anesthesiologists.  
 
Conclusion 
 Transvenous temporary cardiac pacing is an 
indispensable treatment modality for the acute treatment of 
a variety of dysrhythmias, mostly bradyarrhythmias, and 
therefore it is considered a critically important skill for the 
clinician. Its implementation, however, requires both 
competent interventional skills and experience in cardiac 
pacing, as well as continuous care after the successful 
insertion, in order to maximize the potential benefit for the 
patient and to mitigate the risk of complications.  
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